SCM
BCYC

Soleus Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Soleus Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,000
Closed -$695K – 93
2025
Q2 		$695K Buy
+100,000
New +$797K 0.05% 89
2024
Q4 		– Sell
-78,315
Closed -$1.77M – 87
2024
Q3 		$1.77M Buy
78,315
+54,815
+233% +$1.26M 0.14% 81
2024
Q2 		$476K Sell
23,500
-129,500
-85% -$2.93M 0.04% 89
2024
Q1 		$3.81M Buy
153,000
+58,000
+61% +$1.23M 0.28% 68
2023
Q4 		$1.72M Sell
95,000
-296,800
-76% -$4.91M 0.19% 56
2023
Q3 		$7.87M Sell
391,800
-20,000
-5% -$457K 0.73% 39
2023
Q2 		$10.5M Hold
411,800
– – 1.17% 26
2023
Q1 		$8.76M Buy
411,800
+153,400
+59% +$3.85M 0.91% 31
2022
Q4 		$7.65M Buy
+258,400
New +$6.93M 1.1% 29
2022
Q1 		– Sell
-10,250
Closed -$624K – 70
2021
Q4 		$624K Buy
+10,250
New +$566K 0.06% 63

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Soleus Capital Management's BCYC Position: Q3 2025 in Review

Soleus Capital Management sold out of Bicycle Therapeutics (BCYC) in Q3 2025, closing a stake of 100,000 shares — an estimated $695K sold.

Soleus Capital Management first reported a position in BCYC in Q4 2021 and held it in 10 quarters. The position peaked at $10.5M in Q2 2023. 99 funds tracked by Wall St. Rank hold BCYC as of Q3 2025.

  • Soleus Capital Management reported no remaining Bicycle Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Soleus Capital Management sold 100,000 Bicycle Therapeutics shares in Q3 2025, an estimated $695K.
  • Soleus Capital Management first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 10 quarters.
  • Soleus Capital Management's Bicycle Therapeutics position peaked at $10.5M in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2025.

Based on Soleus Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.